TABLE III.

Univariable and multivariable regression analyses of clinico-demographic factors affecting health utility scores, by health state

Variable	Health utility scores in univariable analysis			Change in health utility scores in multivariable analysis
	Mean	95% ci	p Valuea	β	95% ci	p Valuea
Sex
Women	0.759	0.72 to 0.79	0.053
Men	0.803	0.78 to 0.83
Age at Dx
<65 years	0.787	0.76 to 0.81	0.557
≥65 years	0.773	0.73 to 0.81
Health state
Stable	0.810	0.79 to 0.83	0.012	Reference
Progressing	0.743	0.70 to 0.79		−0.065	−0.113 to −0.017	0.008
Treatment-naïve	0.733	0.62 to 0.84		−0.087	−0.189 to 0.014	0.091
ecog PS at stage IV Dx
0	0.826	0.80 to 0.86	0.003	−0.075	−0.121 to −0.028	0.002
1	0.744	0.71 to 0.78
2	0.818	0.74 to 0.90
Line of treatment
0	0.824	0.77 to 0.88	0.001
1	0.776	0.75 to 0.80
2	0.813	0.79 to 0.84
3	0.843	0.81 to 0.87
≥4	0.762	0.72 to 0.80
Treatment at encounter
Crizotinib	0.787	0.75 to 0.82	0.333
Ceritinib	0.748	0.67 to 0.82
Alectinib	0.845	0.79 to 0.90
Other tki	0.777	0.73 to 0.82
Chemotherapy	0.763	0.68 to 0.85
None or other treatment	0.775	0.73 to 0.82
Metastatic sites
0	0.827	0.79 to 0.86	0.039
1	0.806	0.78 to 0.83
2	0.751	0.70 to 0.80
3	0.723	0.64 to 0.81
4	0.789	0.73 to 0.84
Brain metastasis
No	0.795	0.77 to 0.82	0.191
Yes	0.765	0.73 to 0.80
Bone metastasis
No	0.803	0.78 to 0.83	0.025
Yes	0.751	0.71 to 0.79
Liver metastasis
No	0.787	0.77 to 0.81	0.206
Yes	0.739	0.64 to 0.84
Pleural metastasis
No	0.778	0.75 to 0.80	0.461
Yes	0.799	0.76 to 0.84
Lymph node metastasis
No	0.795	0.77 to 0.82	0.102
Yes	0.755	0.71 to 0.80

ci = confidence interval; Dx = diagnosis; ecog PS = Eastern Cooperative Oncology Group performance status; tki = tyrosine kinase inhibitor.

^aSignificant values shown in boldface type.